The contested decision by the Food and Drug Administration earlier this week to approve a drug to treat Alzheimer’s has renewed concerns about the Biden administration’s prolonged delay in choosing a permanent commissioner to lead the agency. It has also once again exposed the sharp divide between supporters and detractors of the F.D.A.’s interim commissioner, Dr. Janet Woodcock, the longtime chief of the agency’s drug division who has seemed to.